Results 151 to 160 of about 18,145 (196)

Budget impact analysis of the introduction of ranibizumab's biosimilar to the Jordanian joint procurement system. [PDF]

Front Public Health
Hamida JA, Alkhatib NS, Hammour KA, Halloush S, Kurdi A, Balkhi B, Alfayez OM, Mousa R.   +7 more
europepmc   +1 more source

Management of polypoidal choroidal vasculopathy: Malaysian Consensus Guideline 2023. [PDF]

Int J Ophthalmol
Ngah NF, Hashim H, Suan ALL, Mohamed SO, Rajan RS, Abdul Aziz RA, Ahmad Tarmidzi NA, George TM, Yaakub M, Fong K, Cheung CMG, Wong HS, Ma'amor NH, Leman FN, Muhamad NA.   +14 more
europepmc   +1 more source

Anti-vascular endothelial growth factor therapy for posterior segment diseases: Progress, challenges, and the road ahead. [PDF]

Indian J Ophthalmol
Mishra C, Mohanty N, Purohit S, Orugonda U, Patil V.   +4 more
europepmc   +1 more source

Short-term treatment outcomes of the ranibizumab biosimilar CKD-701 for vitreous hemorrhage secondary to proliferative diabetic retinopathy. [PDF]

BMC Ophthalmol
Yu SH, Cho J, Park SM, Kim CG, Kim JH.
europepmc   +1 more source

Comparison of adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema: A global network study. [PDF]

Eye (Lond)
Lee WA, Tsai DH, Cheng MC, Lin YS, Lee CY, Shao SC, Lai EC.   +6 more
europepmc   +1 more source

Comparison of the effectiveness of ranibizumab monotherapy vs. combined panretinal photocoagulation on the regression of neovascularization in proliferative diabetic retinopathy. [PDF]

Front Med (Lausanne)
Wang Y, Wang L, Zheng Z, Xu J, Zhang Z.
europepmc   +1 more source

Real-world cost evaluation of conbercept vs. ranibizumab for retinal and choroidal vascular diseases from 2021 to 2024: evidence from societal and medical insurance perspectives. [PDF]

BMC Public Health
Liu Y, Zhao J, Huang J, Qin Y, Huang Y, Fan H, Zhou W, Han H, You C, Cui Z, Belfort Junior R, Fernandes RAB, Yan H.   +12 more
europepmc   +1 more source

Peep into anti-vascular endothelial growth factor. [PDF]

Indian J Ophthalmol
Verma L, Singh S, Ramachandran O.
europepmc   +1 more source

Proteomic profiling reveals treatment-dependent inflammatory signatures and identifies biomarkers of refractory age-related macular degeneration. [PDF]

Front Pharmacol
Eandi CM, Borgo A, de Oliveira Figueiredo E, de Haro D, Kaufmann DE, Roduit R.   +5 more
europepmc   +1 more source